89Zr标记AlbudAb在健康人中经PET/CT评估的生物分布与清除
该研究将非偶联的AlbudAb(白蛋白结合结构域抗体)GSK3128349以89Zr标记后,对8名健康男性静脉给药1 mg(约15 MBq),并在7天内进行4次全身PET/CT扫描以观察组织分布与清除。结果显示给药与显像耐受良好,AlbudAb表现为类白蛋白药代动力学,肾脏组织/血浆比值最高(0.5–1.5),脑组织/血浆比值0.025提示血脑屏障穿透极少,末端半衰期为18天。
要点
- 89Zr-AlbudAb在健康人中耐受良好,未见药物相关免疫原性或不良事件。
- 肾脏组织/血浆比值最高(0.5–1.5),肾皮质浓度最高,提示肾脏为主要分布与残留器官。
- 脑组织/血浆比值仅0.025,提示AlbudAb穿透血脑屏障极少。
核心结论
- 89Zr-AlbudAb可在低放射性剂量下成功评估健康志愿者的体内分布,给药后AlbudAb与白蛋白快速形成可逆但稳定的复合物,呈现类白蛋白药代动力学并伴有限肾脏清除。
研究设计与样本
- 在8名健康男性中静脉给予单次1 mg(约15 MBq)89Zr标记的非偶联AlbudAb(GSK3128349),7天内完成4次全身PET/CT扫描,并用伽马计数与LC-MS/MS评估血浆药代动力学。
主要发现
- 给药与PET/CT操作耐受良好,无药物相关免疫原性或不良事件;肝、肺、心脏组织/血浆比值在给药后7天内相对稳定,范围为0.1–0.5。
- 脑组织/血浆比值为0.025,提示血脑屏障穿透极少;肌肉、睾丸、胰腺和脾脏比值缓慢升高,反映穿透缓慢和/或89Zr残留。
- 肾脏组织/血浆比值最高(0.5–1.5),肾皮质浓度最高;89Zr-AlbudAb末端半衰期为18天,总受试者暴露约10 mSv。
关键数值与推荐
- 组织/血浆比值:肝、肺、心脏0.1–0.5;脑0.025;肾0.5–1.5;末端半衰期18天;总暴露约10 mSv。
临床怎么用
- 该人体器官特异性分布数据有助于利用AlbudAb平台筛选治疗靶点,并支持治疗性AlbudAb的临床给药方案建模优化。
局限性
- 研究仅纳入8名健康男性,样本量小且人群单一;单次1 mg剂量,观察期最长7天,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Conjugation or fusion to AlbudAbs™ (albumin-binding domain antibodies) is a novel approach to extend the half-life and alter the tissue distribution of biological and small molecule therapeutics. To understand extravasation kinetics and extravascular organ concentrations of AlbudAbs in humans, we studied tissue distribution and elimination of a non-conjugated 89Zr-labeled AlbudAb in healthy volunteers using positron emission tomography/computed tomography (PET/CT). METHODS: A non-conjugated AlbudAb (GSK3128349) was radiolabeled with 89Zr and a single 1 mg (~ 15 MBq) dose intravenously administered to eight healthy males. 89Zr-AlbudAb tissue distribution was followed for up to 7 days with four whole-body PET/CT scans. 89Zr-AlbudAb tissue concentrations were quantified in organs of therapeutic significance, measuring standardized uptake value and tissue/plasma ratios. Plasma pharmacokinetics were assessed by gamma counting and LC-MS/MS of blood samples. RESULTS: 89Zr-AlbudAb administration and PET/CT procedures were well tolerated, with no drug-related immunogenicity or adverse events. 89Zr-AlbudAb rapidly distributed throughout the vasculature, with tissue/plasma ratios in the liver, lungs, and heart relatively stable over 7 days post-dose, ranging between 0.1 and 0.5. The brain tissue/plasma ratio of 0.025 suggested minimal AlbudAb blood-brain barrier penetration. Slowly increasing ratios in muscle, testis, pancreas, and spleen reflected either slow AlbudAb penetration and/or 89Zr residualization in these organs. Across all tissues evaluated, the kidney tissue/plasma ratio was highest (0.5-1.5 range) with highest concentration in the renal cortex. The terminal half-life of the 89Zr-AlbudAb was 18 days. CONCLUSION: Evaluating the biodistribution of 89Zr-AlbudAb in healthy volunteers using a low radioactivity dose was successful (total subject exposure ~ 10 mSv). Results indicated rapid formation of reversible, but stable, complexes between AlbudAb and albumin upon dosing. 89Zr-AlbudAb demonstrated albumin-like pharmacokinetics, including limited renal elimination. This novel organ-specific distribution data for AlbudAbs in humans will facilitate a better selection of drug targets to prosecute using the AlbudAb platform and significantly contribute to modeling work optimizing dosing of therapeutic AlbudAbs in the clinic.
引用
- Thorneloe KS, Sepp A, Zhang S, et al. The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. EJNMMI Res. 2019. PMID: 31115711. doi:10.1186/s13550-019-0514-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。